Evidence map›Paper›PMID 41892477›Full record

ArticleAntibiotics (Basel, Switzerland)2026

Enhanced In Vitro Stability of Bedaquiline with Ascorbic Acid and Pyruvate During Long-Term Incubation in

Sara Batista, Jordi Lamata, Lidia Feliu, Marta Planas, Mariana Fernandez-Pittol, Diego Martinez, Lorena San Nicolás, Griselda Tudó, Julian Gonzalez-Martin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sara BatistaDepartament de Fonaments Clínics, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, c/Casanova 143, 08036 Barcelona, Spain.
Jordi LamataLIPPSO, Departament de Química, Institut de Tecnologia Agroalimentària, Universitat de Girona, Maria Aurèlia Capmany 69, 17003 Girona, Spain.
Lidia FeliuLIPPSO, Departament de Química, Institut de Tecnologia Agroalimentària, Universitat de Girona, Maria Aurèlia Capmany 69, 17003 Girona, Spain.ORCID 0000-0001-9792-6106
Marta PlanasLIPPSO, Departament de Química, Institut de Tecnologia Agroalimentària, Universitat de Girona, Maria Aurèlia Capmany 69, 17003 Girona, Spain.ORCID 0000-0003-4988-4970
Mariana Fernandez-PittolDepartament de Fonaments Clínics, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, c/Casanova 143, 08036 Barcelona, Spain.
Diego MartinezServei de Microbiologia, CDB, Hospital Clínic de Barcelona, c/Villarroel 170, 08036 Barcelona, Spain.
Lorena San NicolásServei de Microbiologia, CDB, Hospital Clínic de Barcelona, c/Villarroel 170, 08036 Barcelona, Spain.
Griselda TudóDepartament de Fonaments Clínics, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, c/Casanova 143, 08036 Barcelona, Spain.ORCID 0000-0002-9241-7051
Julian Gonzalez-MartinDepartament de Fonaments Clínics, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, c/Casanova 143, 08036 Barcelona, Spain.ORCID 0000-0001-7248-6706

Funding

CIBER- Consorcio Centro de Investigación Biomédica en Red, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, and Unión Europea-NextGenerationEU CB21/13/00081Departament d'Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya 2021SGR01569Fundació La Marató de TV3 202513-10Ministerio de Economía y Competitividad, Instituto de Salud Carlos III, cofinanced by the European Regional Development Fund (ERDF, FEDER), "A Way to Achieve Europe", the Spanish Ministry of Health PI2200536Sociedad Española de Neumología y Cirugía Torácica (SEPAR) 1502-23
6 · The paper itself

Abstract

backgroundDrug susceptibility testing in

objectivesThis study evaluated the in vitro stability of several antibiotics, including recently introduced agents (bedaquiline [BDQ], pretomanid, delamanid and clofazimine) used for treating multidrug-resistant mycobacteriosis (linezolid and moxifloxacin), and those commonly included in combination regimens (rifampicin, isoniazid, ethambutol and clarithromycin).

methodsAntibiotics were pre-incubated at 37 °C before MIC determination and those exhibiting two or more dilutions in MIC were further tested in combination with ascorbic acid (AA) and pyruvate (P).

resultsAll antibiotics demonstrated stability except BDQ, which showed significant MIC variation after pre-incubation, which was prevented when BDQ was combined with AA and P.

conclusionsThese findings suggest that the combined use of AA and P may serve as an effective stabilizing strategy for BDQ during MIC determination.

Indexed as

antibiotic stabilityantimicrobial susceptibility testascorbic acidbedaquilineminimum inhibitory concentration (MIC)Mycobacterium avium complexMycobacterium tuberculosispyruvate

Identifiers

PMID41892477
PMCPMC13024311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.